187 related articles for article (PubMed ID: 37526549)
21. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma.
Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S
J Control Release; 2024 Jun; 370():835-865. PubMed ID: 38744345
[TBL] [Abstract][Full Text] [Related]
22. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
[TBL] [Abstract][Full Text] [Related]
23. Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG.
Tinkle CL; Broniscer A; Chiang J; Campagne O; Huang J; Orr BA; Li X; Patay Z; Zhang J; Baker SJ; Merchant TE; Jain V; Onar-Thomas A; Stewart CF; Wetmore C; Gajjar A
Neurooncol Adv; 2021; 3(1):vdab179. PubMed ID: 34993482
[TBL] [Abstract][Full Text] [Related]
24. Oxaliplatin and [Pt(R,R-DACH)(panobinostat
Boulet MHC; Marsh LK; Howarth A; Woolman A; Farrer NJ
Dalton Trans; 2020 May; 49(17):5703-5710. PubMed ID: 32297619
[TBL] [Abstract][Full Text] [Related]
25. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance.
Deligne C; Hachani J; Duban-Deweer S; Meignan S; Leblond P; Carcaboso AM; Sano Y; Shimizu F; Kanda T; Gosselet F; Dehouck MP; Mysiorek C
Fluids Barriers CNS; 2020 Jun; 17(1):37. PubMed ID: 32487241
[TBL] [Abstract][Full Text] [Related]
26. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial.
Souweidane MM; Kramer K; Pandit-Taskar N; Zhou Z; Haque S; Zanzonico P; Carrasquillo JA; Lyashchenko SK; Thakur SB; Donzelli M; Turner RS; Lewis JS; Cheung NV; Larson SM; Dunkel IJ
Lancet Oncol; 2018 Aug; 19(8):1040-1050. PubMed ID: 29914796
[TBL] [Abstract][Full Text] [Related]
27. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
[TBL] [Abstract][Full Text] [Related]
29. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Vitanza NA; Biery MC; Myers C; Ferguson E; Zheng Y; Girard EJ; Przystal JM; Park G; Noll A; Pakiam F; Winter CA; Morris SM; Sarthy J; Cole BL; Leary SES; Crane C; Lieberman NAP; Mueller S; Nazarian J; Gottardo R; Brusniak MY; Mhyre AJ; Olson JM
Neuro Oncol; 2021 Mar; 23(3):376-386. PubMed ID: 33130903
[TBL] [Abstract][Full Text] [Related]
30. Influence of socioeconomic status on clinical outcomes of diffuse midline glioma and diffuse intrinsic pontine glioma.
Lee JH; Holste KG; Bah MG; Franson AT; Garton HJL; Maher CO; Muraszko KM
J Neurosurg Pediatr; 2024 Jun; 33(6):507-515. PubMed ID: 38489807
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
32. Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG).
Gwak HS; Park HJ
Crit Rev Oncol Hematol; 2017 Dec; 120():111-119. PubMed ID: 29198324
[TBL] [Abstract][Full Text] [Related]
33. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.
Grasso CS; Tang Y; Truffaux N; Berlow NE; Liu L; Debily MA; Quist MJ; Davis LE; Huang EC; Woo PJ; Ponnuswami A; Chen S; Johung TB; Sun W; Kogiso M; Du Y; Qi L; Huang Y; Hütt-Cabezas M; Warren KE; Le Dret L; Meltzer PS; Mao H; Quezado M; van Vuurden DG; Abraham J; Fouladi M; Svalina MN; Wang N; Hawkins C; Nazarian J; Alonso MM; Raabe EH; Hulleman E; Spellman PT; Li XN; Keller C; Pal R; Grill J; Monje M
Nat Med; 2015 Jun; 21(6):555-9. PubMed ID: 25939062
[TBL] [Abstract][Full Text] [Related]
34. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S
J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091
[TBL] [Abstract][Full Text] [Related]
35. Development of a clinical scale for assessment of patients with diffuse intrinsic pontine glioma (DIPG) receiving experimental therapy: the PONScore.
Hollingworth MA; Zacharoulis S
J Neurooncol; 2020 Sep; 149(2):263-272. PubMed ID: 32902768
[TBL] [Abstract][Full Text] [Related]
36. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
[TBL] [Abstract][Full Text] [Related]
37. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
Pollack IF; Jakacki RI; Blaney SM; Hancock ML; Kieran MW; Phillips P; Kun LE; Friedman H; Packer R; Banerjee A; Geyer JR; Goldman S; Poussaint TY; Krasin MJ; Wang Y; Hayes M; Murgo A; Weiner S; Boyett JM
Neuro Oncol; 2007 Apr; 9(2):145-60. PubMed ID: 17293590
[TBL] [Abstract][Full Text] [Related]
39. Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care.
Williams JR; Young CC; Vitanza NA; McGrath M; Feroze AH; Browd SR; Hauptman JS
Neurosurg Focus; 2020 Jan; 48(1):E4. PubMed ID: 31896081
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma.
Noll A; Myers C; Biery MC; Meechan M; Tahiri S; Rajendran A; Berens ME; Paine D; Byron S; Zhang J; Winter C; Pakiam F; Leary SES; Cole BL; Jackson ER; Dun MD; Foster JB; Evans MK; Pattwell SS; Olson JM; Vitanza NA
Neoplasia; 2023 Sep; 43():100921. PubMed ID: 37603953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
